
Giacomo M Bruno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370120/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overview of Nutraceuticals and Cardiometabolic Diseases following Socio-Economic Analysis. Endocrines, 2022, 3, 255-295.	0.4	1
2	Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 503-518.	0.7	4
3	Wastage of gonadotropins during IVF cycles: Real life data from two Italian infertility centers. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 267, 56-60.	0.5	1
4	Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Health Services Insights, 2020, 13, 117863292092998.	0.6	1
5	Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. Risk Management and Healthcare Policy, 2020, Volume 13, 43-53.	1.2	11
6	<p>Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 177-189.	0.7	9
7	Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 477-491.	0.7	9
8	The preventive effect on respiratory tract infections of Oscillococcinum [®] . A cost-effectiveness analysis. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 75-82.	0.7	2
9	Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 413-421.	0.7	7